Adocia S.A. (ADOIF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Adocia S.A. (ADOIF) with AI Score 52/100 (Hold). Adocia S. A. is a clinical-stage biotechnology company focused on developing innovative formulations of therapeutic proteins and peptides for diabetes and metabolic diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Adocia S.A. (ADOIF) Healthcare & Pipeline Overview
Adocia S.A., a French clinical-stage biotech, leverages its BioChaperone platform to develop improved formulations of approved therapeutic proteins for diabetes and metabolic diseases. Their pipeline focuses on enhancing insulin therapies and exploring multi-hormonal treatments for obesity, positioning them in a competitive landscape of pharmaceutical innovation.
Investment Thesis
Adocia S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's BioChaperone platform offers the potential to create differentiated insulin and multi-hormonal therapies. Key value drivers include the successful clinical development and commercialization of BioChaperone Lispro and BioChaperone Combo, particularly in partnership with Tonghua Dongbao. Upcoming clinical trial results for its lead candidates represent near-term catalysts. However, the company's negative profit and gross margins (-84.3% and -77.5% respectively) and reliance on partnerships introduce significant financial and operational risks. The company's market capitalization is approximately $0.10 billion, reflecting the speculative nature of its pipeline.
Based on FMP financials and quantitative analysis
Key Highlights
- Adocia S.A. specializes in developing innovative formulations of therapeutic proteins and peptides for diabetes and metabolic diseases.
- The company's proprietary BioChaperone platform aims to enhance the efficacy and safety profiles of existing treatments.
- Adocia's clinical pipeline includes ultra-rapid insulin formulations (BioChaperone Lispro) and combination therapies (BioChaperone Combo).
- A strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. focuses on commercializing BioChaperone Lispro and Combo in China and other Asian and Middle Eastern territories.
- The company's preclinical pipeline explores bi-hormonal and multi-hormonal products for the treatment of obesity.
Competitors & Peers
Strengths
- Proprietary BioChaperone platform for enhanced drug delivery.
- Strategic partnership with Tonghua Dongbao for Asian markets.
- Diverse pipeline of insulin and multi-hormonal therapies.
- Focus on addressing unmet needs in diabetes and obesity treatment.
Weaknesses
- Negative profit and gross margins.
- Reliance on partnerships for commercialization.
- Limited financial resources.
- High dependence on clinical trial success.
Catalysts
- Upcoming: Clinical trial results for BioChaperone Lispro.
- Upcoming: Regulatory submissions for BioChaperone Combo.
- Ongoing: Expansion of strategic partnerships.
- Ongoing: Advancement of multi-hormonal obesity programs.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources.
- Potential: Dependence on key partnerships.
Growth Opportunities
- BioChaperone Lispro Commercialization: Adocia's lead product, BioChaperone Lispro, represents a significant growth opportunity. This ultra-rapid insulin formulation aims to improve post-meal glucose control for diabetic patients. Successful clinical trials and subsequent commercialization, particularly in partnership with Tonghua Dongbao in China, could drive substantial revenue growth. The global market for insulin therapies is estimated to be several billion dollars annually, offering a large potential market for BioChaperone Lispro.
- BioChaperone Combo Development: The BioChaperone Combo, a combination of insulin glargine and rapid-acting insulin lispro, addresses the need for more convenient and effective diabetes management. Positive clinical trial results and regulatory approvals could position BioChaperone Combo as a competitive alternative to existing combination therapies. The market for combination diabetes drugs is growing, driven by the desire for simplified treatment regimens.
- Expansion of Strategic Partnerships: Adocia's strategic alliance with Tonghua Dongbao is crucial for its growth in the Asian market. Expanding partnerships with other pharmaceutical companies could provide access to new markets and funding for further development of its pipeline. Strategic collaborations can accelerate the commercialization of Adocia's products and reduce its financial risk.
- Advancement of Multi-Hormonal Obesity Programs: Adocia's preclinical pipeline includes multi-hormonal products for the treatment of obesity, such as BioChaperone GluExe and PramExe. These programs target multiple pathways involved in appetite regulation and energy expenditure. Successful preclinical and clinical development could lead to novel obesity therapies with significant market potential. The global obesity market is estimated to be worth billions of dollars, reflecting the growing prevalence of obesity worldwide.
- Lifecycle Management of Existing Products: As existing insulin therapies face increasing competition from biosimilars, Adocia's BioChaperone platform offers the potential to develop improved versions of these products. By enhancing the efficacy and safety profiles of established insulin formulations, Adocia can extend their market life and maintain revenue streams. Lifecycle management strategies are essential for pharmaceutical companies to sustain growth in a competitive market.
Opportunities
- Expanding partnerships with other pharmaceutical companies.
- Successful clinical development of lead candidates.
- Growing demand for improved diabetes and obesity therapies.
- Potential for regulatory approvals in key markets.
Threats
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Biosimilar competition.
Competitive Advantages
- Proprietary BioChaperone technological platform.
- Expertise in formulation development.
- Strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pipeline of innovative insulin and multi-hormonal therapies.
About ADOIF
Adocia S.A., founded in 2005 and headquartered in Lyon, France, is a biotechnology company specializing in the research and development of innovative formulations of pre-approved therapeutic proteins and peptides. The company targets diabetes and other metabolic diseases, leveraging its proprietary BioChaperone technological platform. This platform is designed to optimize the performance of therapeutic proteins, aiming to improve their efficacy, safety, and patient convenience. Adocia's clinical product pipeline features insulin formulations like BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro. Other clinical-stage products include BioChaperone Combo, a combination of insulin glargine and rapid-acting insulin lispro, and BioChaperone LisPram, combining prandial insulin with pramlintide. The company is also developing BioChaperone Glucagon, an aqueous formulation of human glucagon for hypoglycemia treatment, and M1Pram, a metabolite of insulin glargine and pramlintide. Adocia's preclinical pipeline includes bi-hormonal and multi-hormonal products for obesity, such as BioChaperone GluExe, PramExe, and BioChaperone PramGluExe. Adocia has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories.
What They Do
- Researches and develops formulations of therapeutic proteins and peptides.
- Focuses on treatments for diabetes and other metabolic diseases.
- Utilizes its proprietary BioChaperone technological platform to optimize protein performance.
- Develops ultra-rapid insulin formulations.
- Creates combination therapies for diabetes management.
- Explores multi-hormonal products for obesity treatment.
Business Model
- Develops proprietary formulations of existing therapeutic proteins and peptides.
- Out-licenses its products to pharmaceutical companies for commercialization.
- Generates revenue through upfront payments, milestone payments, and royalties on sales.
- Focuses on partnering with companies that have established distribution networks.
Industry Context
Adocia S.A. operates in the competitive biotechnology industry, specifically targeting the diabetes and obesity markets. The diabetes market is driven by the increasing prevalence of the disease globally, with a growing demand for improved insulin therapies. The obesity market is also expanding, fueled by lifestyle changes and a greater awareness of health risks. Adocia competes with established pharmaceutical companies and other biotech firms developing novel treatments for these conditions. Success depends on demonstrating superior efficacy, safety, and convenience compared to existing therapies.
Key Customers
- Pharmaceutical companies seeking to expand their diabetes and obesity portfolios.
- Patients with diabetes and other metabolic diseases.
- Healthcare providers who prescribe and administer Adocia's products.
- Tonghua Dongbao Pharmaceutical Co., Ltd. (strategic alliance partner).
Financials
Chart & Info
Adocia S.A. (ADOIF) stock price: Price data unavailable
Latest News
No recent news available for ADOIF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADOIF.
Price Targets
Wall Street price target analysis for ADOIF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ADOIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Olivier Soula
Chief Executive Officer
Olivier Soula serves as the Chief Executive Officer of Adocia S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions, contributing to strategic planning, business development, and product commercialization. Soula's expertise spans across multiple therapeutic areas, with a particular focus on metabolic diseases. His educational credentials and previous roles have equipped him with the skills necessary to lead Adocia through its clinical development programs and commercialization efforts.
Track Record: Under Olivier Soula's leadership, Adocia S.A. has focused on advancing its clinical pipeline, particularly the BioChaperone Lispro and BioChaperone Combo programs. He has overseen the strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd., which is critical for the company's expansion in the Asian market. Soula has also guided the company through various financing rounds and corporate milestones.
ADOIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Adocia S.A. (ADOIF) may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and may be subject to less regulatory oversight than exchange-listed companies. Investing in OTC Other stocks carries significantly higher risks due to the potential for fraud, lack of liquidity, and limited transparency. Stocks on major exchanges like NYSE or NASDAQ must meet stringent listing requirements, including minimum share price, market capitalization, and financial reporting standards, offering greater investor protection.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume and liquidity can lead to price volatility.
- Potential for delisting or trading suspensions.
- Higher risk of fraud or manipulation compared to exchange-listed companies.
- OTC Other stocks are subject to less regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capitalization structure.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investing.
- Strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd.
- Focus on developing innovative therapies for diabetes and obesity.
- Proprietary BioChaperone technological platform.
- Clinical-stage product pipeline.
What Investors Ask About Adocia S.A. (ADOIF)
What does Adocia S.A. do?
Adocia S.A. is a clinical-stage biotechnology company that specializes in developing innovative formulations of therapeutic proteins and peptides, primarily focused on diabetes and metabolic diseases. The company's core technology is its proprietary BioChaperone platform, which aims to enhance the efficacy and safety of existing treatments. Adocia's business model centers around developing these improved formulations and then out-licensing them to larger pharmaceutical companies for commercialization, generating revenue through upfront payments, milestone payments, and royalties on sales.
What do analysts say about ADOIF stock?
AI analysis is pending for ADOIF, so there is no current analyst consensus available. Investors should monitor for updates from financial analysts, focusing on key valuation metrics such as price-to-earnings ratio (currently negative at -9.45), market capitalization ($0.10B), and growth prospects related to its clinical pipeline. The company's strategic alliance with Tonghua Dongbao and the potential commercialization of BioChaperone Lispro and Combo are important factors to consider. However, investors should also be aware of the risks associated with clinical-stage biotechnology companies.
What are the main risks for ADOIF?
Adocia S.A. faces several key risks inherent to the biotechnology industry and its specific business model. Clinical trial failures represent a significant risk, as the success of its pipeline depends on positive clinical data. Regulatory hurdles and competition from established pharmaceutical companies also pose challenges. Financially, the company's negative profit and gross margins (-84.3% and -77.5% respectively) and reliance on partnerships create vulnerability. Additionally, as an OTC-listed company, ADOIF carries risks associated with lower liquidity and transparency.
What are the key factors to evaluate for ADOIF?
Adocia S.A. (ADOIF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary BioChaperone platform for enhanced drug delivery.. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does ADOIF data refresh on this page?
ADOIF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ADOIF's recent stock price performance?
Recent price movement in Adocia S.A. (ADOIF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary BioChaperone platform for enhanced drug delivery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ADOIF overvalued or undervalued right now?
Determining whether Adocia S.A. (ADOIF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ADOIF?
Before investing in Adocia S.A. (ADOIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may have limited reliability.